157 related articles for article (PubMed ID: 9881093)
21. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
Criscione L; de Gasparo M; Bühlmayer P; Whitebread S; Ramjoué HP; Wood J
Br J Pharmacol; 1993 Oct; 110(2):761-71. PubMed ID: 8242249
[TBL] [Abstract][Full Text] [Related]
22. Discovery of losartan, the first angiotensin II receptor antagonist.
Timmermans PB; Duncia JV; Carini DJ; Chiu AT; Wong PC; Wexler RR; Smith RD
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S3-18. PubMed ID: 8583479
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
24. Design and synthesis of new tetrazolyl- and carboxy-biphenylylmethyl-quinazolin-4-one derivatives as angiotensin II AT1 receptor antagonists.
Ismail MA; Barker S; Abou el-Ella DA; Abouzid KA; Toubar RA; Todd MH
J Med Chem; 2006 Mar; 49(5):1526-35. PubMed ID: 16509571
[TBL] [Abstract][Full Text] [Related]
25. A new series of imidazolones: highly specific and potent nonpeptide AT1 angiotensin II receptor antagonists.
Bernhart CA; Perreaut PM; Ferrari BP; Muneaux YA; Assens JL; Clément J; Haudricourt F; Muneaux CF; Taillades JE; Vignal MA
J Med Chem; 1993 Oct; 36(22):3371-80. PubMed ID: 8230127
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 3D structures and AT(1) binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan.
Le Bourdonnec B; Cauvin C; Meulon E; Yous S; Goossens JF; Durant F; Houssin R; Hénichart JP
J Med Chem; 2002 Oct; 45(21):4794-8. PubMed ID: 12361407
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin II receptor inhibition. A new therapeutic principle.
Messerli FH; Weber MA; Brunner HR
Arch Intern Med; 1996 Sep; 156(17):1957-65. PubMed ID: 8823149
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
[TBL] [Abstract][Full Text] [Related]
31. Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives.
Bühlmayer P; Criscione L; Fuhrer W; Furet P; de Gasparo M; Stutz S; Whitebread S
J Med Chem; 1991 Oct; 34(10):3105-14. PubMed ID: 1920360
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II receptor antagonists: the prototype losartan.
Schaefer KL; Porter JA
Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
[TBL] [Abstract][Full Text] [Related]
33. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and pharmacological evaluation of 5-oxo-1,2,4-oxadiazole derivatives as AT1 antagonists with antihypertension activities.
Zhu W; Bao X; Ren H; Liao P; Zhu W; Yan Y; Wang L; Chen Z
Clin Exp Hypertens; 2016; 38(5):435-42. PubMed ID: 27362285
[TBL] [Abstract][Full Text] [Related]
35. Dihydropyrimidine angiotensin II receptor antagonists.
Atwal KS; Ahmed SZ; Bird JE; Delaney CL; Dickinson KE; Ferrara FN; Hedberg A; Miller AV; Moreland S; O'Reilly BC
J Med Chem; 1992 Dec; 35(25):4751-63. PubMed ID: 1469703
[TBL] [Abstract][Full Text] [Related]
36. Losartan: the first angiotensin receptor antagonist in clinical use.
Beevers DG
J Hum Hypertens; 1995 Nov; 9 Suppl 5():S1. PubMed ID: 8583475
[No Abstract] [Full Text] [Related]
37. Synthesis and angiotensin II receptor antagonist activity of C-linked pyrazole derivatives.
Nicolaï E; Curé G; Goyard J; Kirchner M; Teulon JM; Versigny A; Cazes M; Virone-Oddos A; Caussade F; Cloarec A
Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1617-30. PubMed ID: 7954914
[TBL] [Abstract][Full Text] [Related]
38. (Dipropylphenoxy)phenylacetic acids: a new generation of nonpeptide angiotensin II receptor antagonists.
Dhanoa DS; Bagley SW; Chang RS; Lotti VJ; Chen TB; Kivlighn SD; Zingaro GJ; Siegl PK; Chakravarty PK; Patchett AA
J Med Chem; 1993 Nov; 36(23):3738-42. PubMed ID: 8246245
[No Abstract] [Full Text] [Related]
39. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay.
Belz GG; Butzer R; Kober S; Mang C; Mutschler E
Clin Pharmacol Ther; 1999 Oct; 66(4):367-73. PubMed ID: 10546920
[TBL] [Abstract][Full Text] [Related]
40. Structure elucidation and conformational study of V8: a novel synthetic non peptide AT(1) antagonist.
Zoumpoulakis P; Politi A; Grdadolnik SG; Matsoukas J; Mavromoustakos T
J Pharm Biomed Anal; 2006 Mar; 40(5):1097-104. PubMed ID: 16260110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
